Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMJWT3X)

Drug Name
HONOKIOL Drug Info
Synonyms
Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; Honokiol,(S); UNII-11513CCO0N; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; 11513CCO0N; 3',5-diallyl-2,4'-biphenyldiol; AK-25837; 5,3& -Diallyl-2,4& Q-100425; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; houpa
Cross-matching ID
PubChem CID
72303
ChEBI ID
CHEMBL16901
CAS Number
CAS 35354-74-6
TTD Drug ID
D04DQJ

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Pantothenate and CoA biosynthesis 1.92 1.37e-2 14/21 (66.67%) BCAT1;AASDHPPT;ALDH1B1;...
Ribosome biogenesis in eukaryotes 1.87 1.72e-2 52/108 (48.15%) NVL;IMP4;IMP3;...
Citrate cycle (TCA cycle) 1.82 3.44e-2 30/30 (100%) SDHA;DLD;IDH3A;...
Base excision repair 1.81 2.58e-2 29/33 (87.88%) POLE2;PCNA;FEN1;...
DNA replication 1.77 3.44e-2 34/36 (94.44%) POLE2;PCNA;FEN1;...
Fanconi anemia pathway 1.74 3.90e-2 36/54 (66.67%) FANCI;RAD51C;RMI1;...
Thyroid cancer -1.65 4.94e-2 36/37 (97.3%) NCOA4;MAPK3;RXRB;...
Coronavirus disease -1.67 4.32e-2 215/232 (92.67%) C7;RPL18;MAPK10;...
Nicotine addiction -1.69 3.71e-2 32/40 (80%) GABRG2;CHRNB2;SLC17A7;...
Primary immunodeficiency -1.70 3.63e-2 33/38 (86.84%) CD8A;ZAP70;CD3D;...
Endometrial cancer -1.70 3.84e-2 56/58 (96.55%) MAP2K2;CTNNA2;ILK;...
Neutrophil extracellular trap formation -1.71 3.99e-2 101/189 (53.44%) NCF2;HDAC6;ITGAL;...
Tyrosine metabolism -1.72 3.84e-2 30/36 (83.33%) ADH1A;TPO;ADH6;...
Lysosome -1.72 3.66e-2 115/128 (89.84%) ARSA;GALC;SLC17A5;...
Th17 cell differentiation -1.74 2.92e-2 95/107 (88.79%) RELA;IL21R;PLCG1;...
Necroptosis -1.75 2.85e-2 113/159 (71.07%) CFLAR;PYGM;RIPK1;...
Glycosylphosphatidylinositol (GPI)-anchor biosynthesis -1.75 3.09e-2 20/26 (76.92%) PIGN;GPLD1;PIGC;...
T cell receptor signaling pathway -1.76 2.91e-2 93/104 (89.42%) MAP3K7;PAK4;BCL10;...
Allograft rejection -1.76 3.20e-2 32/38 (84.21%) HLA-DMB;FAS;IL10;...
Cell adhesion molecules -1.78 3.27e-2 118/148 (79.73%) PDCD1LG2;NCAM1;CD8B;...
Other glycan degradation -1.79 3.20e-2 13/18 (72.22%) ENGASE;MAN2B1;MAN2B2;...
Metabolism of xenobiotics by cytochrome P450 -1.82 2.37e-2 49/77 (63.64%) GSTT2;GSTT1;AKR7A2;...
Basal cell carcinoma -1.84 2.56e-2 41/63 (65.08%) CTNNB1;AXIN1;WNT5A;...
Type I diabetes mellitus -1.85 2.81e-2 38/43 (88.37%) HLA-DMB;FAS;ICA1;...
Graft-versus-host disease -1.85 3.52e-2 32/42 (76.19%) HLA-G;CD28;CD80;...
Autoimmune thyroid disease -1.96 0.00e+0 46/53 (86.79%) HLA-DMB;FAS;IL10;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -2.03 0.00e+0 79/89 (88.76%) MAP2K2;RELA;PLCG1;...
Th1 and Th2 cell differentiation -2.13 0.00e+0 80/92 (86.96%) RELA;PLCG1;IFNG;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Osteosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
U-2 OS CVCL_0042 Homo sapiens 0.12uM - 10uM 6H, 24H, 48H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 6H, 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.04uM - 10uM 6H, 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 6H, 24H, 48H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
PC-3 CVCL_0035 Homo sapiens 0.04uM - 10uM 6H, 24H
VCaP CVCL_2235 Homo sapiens 10uM 6H, 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 6H, 24H